Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemvidutide in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH)
NCT05989711Phase 2Completed
- Sponsor
- Altimmune, Inc.
- Start
- Jul 2023
- Primary completion
- Nov 2025
- Modality
- Recombinant Proteins and Enzymes, Modified Peptides
- Countries
- 3
01
Overview
A Phase 2 trial of pemvidutide in Nonalcoholic steatohepatitis (NASH), sponsored by Altimmune, Inc.. Started Jul 2023; status: completed.
02
Drugs
pemvidutide
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05989711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05989711.